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Pancreatic lipase (PL) plays a major role in the hydrolysis of dietary triglycerides to monoglycerides and free fatty acids 
in the small intestine before absorption of fats. The excessive consumption of dietary fat (triglyceride) and not to utilize it 
for energy production can cause an increase in obesity. Obesity is one of the serious health problem in the world and leads to 
many diseases such as some types of cancer, heart disease, gallstones, sleep apnea, fatty liver disease, type-2 diabetes, 
hypertension, coronary artery disease. Therefore, lipase is the target enzyme to prevent these diseases and the inhibitors of 
lipase are very important molecules as drug candidate molecules. In this study, fifteen new heterocyclic compounds have 
been synthesized starting from 2-[3-(4-chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2,4-triazol-4-yl]-acetohydrazide and their 
anti-lipase activities have been examined. According to in vitro inhibition studies, molecule 2e is found to be the most 
potent inhibitor with the lowest IC50 value. Docking studies' results have substantially supported this result and it is seen that 
compound 2e is one of the four molecules with the highest binding affinity. This molecule binds to the enzyme in its binding 
pocket by means of weak interactions with mainly Ile79, Asp80, Val260, Arg257 and His264. 
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Obesity is one of the most widely recognized healty 
issue in the world and lead to many serious diseases 
such as some types of cancer, heart disease, 
gallstones, sleep apnea, fatty liver disease, type-2 
diabetes, hypertension, coronary artery disease
1
. 
Pancreatic lipase (PL) is a key enzyme which 
hydrolyzes of dietary triglycerides to monoglycerides 
and free fatty acids. The hydrolisation is a crucial step 
before absorption of fat by epithelial cells in the small 
intestine. Excessive dietary fat (triacylglycerols) 
consumption and not utilized for energy expenditure 
is a factor to increasing prevalence of obesity
2,3
. The 
decrease of dietary fat absorption with inhibition of 
PL is represented as a novel approach in obesity 
treatment
2
. Orlistat is presently Europe’s only 
clinically approved drug to manage obesity and used 
for reducing fat absorption by behaving as an efficient 
PL inhibitor in the small intestine
4,5
. However, some 
adverse effects of orlistat have been recorded such as 




Heterocycles are commonly used in the structure of 
commercially available drugs and they are the most 
synthesized compounds found in the discovery of new 
drugs
8
. In 2010, more than 80% of medicines sold in 
the US contain at least one heterocyclic fragment in 
their structure
9
. The most common heterocyclic 
structures are five- and six-membered rings containing 
nitrogen, oxygen and sulfur
10
.1,2,4-triazoles, the most 
prevalent of the five-membered heterocycles carrying 
three nitrogen atoms, have various pharmacological 
properties, such as anticonvulsants, antimicrobial, 
antifungal, antioxidant, antiviral, antitumor and anti-
HIV activities
11-13
. On the other hand, 1,2,4-triazole 
moieties are also found in the structure of various 
commercially available drugs, e.g. Anastrozole, 
Letrozole (to treat breast cancer); Fluconazole, 
Itraconazole, Posaconazole, Voriconazole (to treat 
fungal infections); Ribavirin (to treat respiratory 
syncytial virus); Rizatriptan (to treat migraine 




Another important group commonly used in the 
field of heterocyclic chemistry is mercapto-1,2,4-
triazoles which are used in the field of medicinal 
chemistry and materials science
18-20
. At the same time, 
the presence of sulfur-containing compounds in drugs 
increases their pharmacokinetic properties such as 
reduce side-effects, increase water solubility, decrease 
lipophilicity and create an easy hydrogen bond
21-23
. 




In the present study, starting from 2-[5-(4-
chlorobenzyl)-3-(4-chlorophenyl)-1H-1,2,4-triazol-1-
yl] acetohydrazide, the fifteen new heterocyclic 
compounds were synthesized and screened for their 
lipase inhibitor efficiencies by performing 
biochemical activity and molecular modelling studies. 
 
Results and Discussion 
 
Chemistry 
The synthetic steps of the 1,2,4-triazole derivatives 
(2-4) are shown in Scheme I. Compound 1, used as 
starting material, was synthesized according to the 
method previously published24. The structures of the 




C-NMR, mass spectra and elemental 
analysis (except 2b, 3a and 3d compounds) techniques. 
2-[5-(4-chlorobenzyl)-3-(4-chlorophenyl)-1H-1,2,4-
triazole-1-yl]acetohydrazide (1) was reacted with 
suitable isothiocynates in ethanol gave 2-{[3-(4-
chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2,4-triazol-4-yl] 
acetyl}-4-alkyl/aryl thiosemicarbazides (2a-e). The FT-
IR spectra of thiosemicarbazides displayed absorption 
peaks at about 3105-3392 cm-1 for NH, about 1690 cm-
1
 for C=O and about 1278 cm
-1
 for C=S groups. In the 
1
H-NMR spectrum, the NH2 resonance belonging to 
hydrazide derivative (1) disappeared at 4.92 ppm, and 
three new NH signals were observed at about 8.60, 
9.50 and 10.50 ppm. In the 
13
C-NMR spectra, C=O and 
C=S carbons were resonated at about 166 and 181 
ppm, but C=S carbons of 2b and 2e compounds and 
C=O carbon of 2e compound did not appear. The 
cyclization of 2a-e with 2N NaOH resulted in the 
formation of 1,2,4-triazole derivatives (3a-e). 
Compounds 3a-e can exist thiol-thione tautomeric 
forms. In the thiol form the -SH protons are seen at 
about 13-14 ppm, while the -NH protons in the thion 
form appear between 9-12 ppm
25-27
. In the FT-IR 
spectra, NH and C=S signals were observed at about 
3010 and 1276 cm
-1
, respectively. In the 
1
H-NMR 
spectra of these compounds, the SH signals were 
shown as a singlet between 13.76-14.06 ppm. 
Moreover, the C-SH carbons resonated 167.54-169.16 
ppm in the 
13
C-NMR spectra. According to these data, 
these compounds predominantly exist, in solid state, in 
the thione form, and in liquid state, in the thiol form25-
27
. Compounds 3a-e reacted with formaldehyde and  
1-phenylpiperazine in DMF medium to give  
N-Mannich bases (4a-e). In the FT-IR spectrum of  
4a-e characteristic absorption bands were shown at  
about 1232 cm
-1
 (C=S) and 1160 cm
-1
 (N-CH2-N, 





spectrums of 4a-e CH2 protons and carbons of the  
N-CH2-N group were observed at about 5.12 and  
54.27 ppm, respectively. 
 
 
Scheme I — Synthetic pathway to 1,2,4-triazole substituted compounds 






Optimization and inhibition studies for porcine pancreatic lipase 
(PPL) activity 
Before inhibition studies, PPL activity was 
optimized (Table I). These results showed that PPL 
had an optimum temperature and pH as 37°C and 8.0, 
respectively. Optimum enzyme concentration and  
Km value were also determined as 400 µg/mL and 
140 µM p-NPB, respectively. Inhibitory potencies of 
the compounds which are newly synthesized in this 
study on pancreatic lipase activity were biochemically 
examined and then IC50 values were calculated 
(Table I). In the presence of 3b, 3c and 3d molecules 
up to their 500 µM concentrations in the reaction 
mixture, no inhibitions were observed. Other 
molecules could not be examined in their over 
concentrations of 200 or 500 µM. Among the 
examined organic molecules, 2e showed the best  
anti-lipase activity with IC50 value of 112.3±5.1 µM 
(it corresponds to 61.3±2.8 µg/mL). The observed 
maximum percentage inhibition for other molecules 
was found in range of 4.2-47.0. IC50 value of Orlistat 
as a reference inhibitor molecule was determined to 
be 0.050 µM. Although orlistat is the only anti-
obesity drug approved by Europe, it has some side 
effects such as steatorrhea, fecal urgency and 
incontinence6,7. In the light of this information, 2e can 
be considered as an alternative to orlistat. The lipase 
inhibitory effect of 2e is in a good agreement to  
the early report indicating some triazole 
compounds
25,28-30
. Another study has demonstrated 
that glycosides schaftoside compounds obtained from 
Trigonella foenum-graecum seeds showed the 
inhibitory effect on pancreatic lipase activity, with 
IC50 values between 130 and 330 µg/mL
31
. In another 
study, the inhibition effects of unfractionated 
hydrolysates of yellow field pea on lipase activity had 
been studied and IC50 values were found in mg/mL 
level
32
. The extracts obtained fromseed and shell of 
the fruit of E. tapos inhibited the pancreatic lipase 
activity at different levels. IC50values of these extracts 




Molecular modeling studies 
The organic compounds were investigated by 
docking them into the crystal structure of porcin 
pancreatic lipase in terms of observing their theoretical 
binding potentials to the enzyme binding site and 
determining the interactions between enzyme and them. 
According to these results, compound 3c has the 
lowest binding energy and creates a more stable 
enzyme-inhibitor complex than the other examined 
molecules. However, biochemical kinetic studies 
could not be performed efficiently for this molecule 
because of its higher hydrophobicity and solubulity 
problem and IC50 value could not be determined. In 
vitro kinetic studies showed that only 2e was 
determined as a molecule whose IC50 value was found 
to be the lowest. It was also showed that the results of 
Table I — Optimization of PPL activity and inhibition potentials on PPL of organic compounds 
Optimum and kinetic values for PPL activity Inhibitor compounds IC50, µM Maximum inhibition Binding Affinity 
    % [I], µM (∆G, kcal/mol) 
pH 8.0 2a >200 33.8 ± 2.5 200 −8.4 
Temperature 37°C 2b >200 35.5 ± 1.7 200 −8.5 
Final PPL Conc. 400 µg/mL 2c >200 41.7±2.1 200 −7.5 
Km 140 µM 2d >200 47.0 ±1.3 200 −9.4 
  2e 112.3 ±5.1 71.4 ±1.8 500 −9.4 
  3a >500 7.0 ±0.6 500 −7.8 
  3b − − 500 −8.5 
  3c − − 500 −9.9 
  3d − − 500 −9.8 
  3e >500 4.6 ± 0.2 500 −8.9 
  4a >500 10.4 ± 0.3 500 −9.3 
  4b >500 4.2 ± 0.1 500 −8.3 
  4c >500 4.4 ± 0.3 500 −8.9 
  4d >500 11.4 ± 0.3 500 −9.3 
  4e >500 20.9 ± 0.7 500 −9.6 
  Orlistat 0.050 ± 0.001 54.3 ± 0.3 0.050 − 
“−” No inhibition was observed. 
 




in silico studies and biochemical kinetic studies were 
not consistent in some degree. As known, 
occasionally, the results obtained from docking 
studies and kinetic studies may not fully coincide in 
terms of solubility differences of examined molecules 
and their binding site preferences on enzyme. During 
the docking studies, researchers interact the inhibitor 
molecules with target proteins in its active site. But, it 
is well known that inhibitor may bind to enzyme in 
any site except form active site and then inhibition 
may occur in this way. 
On the other hand, it was easily understood at the 
of the docking studies that compound 2e was one of 
the four molecule with low binding energy (highest 
binding affinity) and binds to the enzyme more 
efficiently than most of the among the examined 
molecules (Table I). Weak interactions of different 
groups of the molecule 2e with the amino acid side 
chains (mainly Ile79, Asp80, Val260, Arg257 and 
His264) in the appropriate position of the enzyme’s 
binding pocket are important in the formation of the 
enzyme-inhibitor complex. Some of these highlighted 
interactions are π-alkyl, π-π-T-shaped, π-sigma, π-
sulfur and conventional interactions (Figure 1).  
Experimental Section 
Chemical reagents purchased from companies such 
as Sigma-Aldrich, Merck, Alfa Aesar and Acros were 
used without further purification. Reaction times were 
monitored by thin layer chromatography (TLC) on 
silica gel and was used ethyl acetate:petroleum ether 
(1:4) as mobile phase. Melting points were recorded 





C NMR (APT) spectra were 
recorded on a Bruker Avance II 400 MHz NMR 
instrument using DMSO-d6. The mass spectra were 
taken by using a Micromass Quattro LC-MS (70 eV) 
instrument. Elemental analysis were executed in a 
Costech Elemental Combustion System CHNS-O 
elemental analyzer. The elemental analysis results of 
all compounds (except 2b, 3a and 3d) were given 
within ± %0.4 of theoretical values. Compound 1 was 
synthesized using our previous study method24. 
 
General Method for the synthesis of compounds, 2a-e 
Acetohydrazide derivative (1) (3.76 g, 0.01 mol) 
and substituted isothiocyanates (0.01 mol) in 50 mL 
absolute ethanol were refluxed, protected from 
moisture, for 4-6 hours. The reaction times were 
monitored by TLC. At the end of this period, the 
reaction mixture was kept in the refrigerator overnight 
and the precipitate solid was filtered off, washed with 
petroleum ether, dried and recrystallized from ethanol 
to give the target compounds. 
2-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]acetyl}-4-methyl thiosemicarbazide, 
2a:Yield:%94 (4.20 g); mp. 208-209°C. FTIR-ATR 
(ν, cm-1): 3392, 3156 (NH), 1689 (C=O), 1605 (C=N), 
1223 (C=S). 
1
HNMR (400 MHz, DMSO-d6) δ: 2.90 
(d, 3H, CH3, J= 8.0 Hz), 4.37 (s, 2H, benzyl CH2), 
5.04 (s, 2H, N-CH2), Ar-H: [7.35-7.41 (m, 4H), 7.50 
(d, 2H, J= 8.0 Hz), 7.93 (d, 2H, J= 8.0 Hz)], 8.08 (s, 
1H, NH), 9.39 (s, 1H, NH), 10.53 (s, 1H, NH); 13C 
(APT) NMR (100 MHz,DMSO-d6) δ: 30.91 (benzyl 
CH2), 31.36 (CH3), 49.99 (N-CH2), Ar-C: [127.84 
(2CH), 128.89 (2CH), 129.30 (2CH), 130.06, 131.32 
(2CH), 131.92, 134.15, 135.66], 157.06 (triazole C-3), 
159.36 (triazole C-5), 166.20 (C=O), 182.61 (C=S);MS 
(m/z, %): 471.05 ([M+Na]
+
; 6), 449.27 ([M]
+
; 10), 
304.23 (100), 219,26 (22), 114.08 (19). Anal. Calcd. 
for C19H18Cl2N6OS: C, 50.78; H, 4.04; N, 18.70; S, 
7.14. Found: C, 50.89; H, 4.09; N, 18.42; S, 7.02%. 
2-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]acetyl}-4-ethyl thiosemicarbazide, 2b: 
Yield:%81 (3.76 g); mp. 198-199°C; FTIR-ATR  
 
 
Fig. 1 — Predicted conformation of the molecule 2e inside the 
binding pocket of porcine pancreatic lipase (A) general projection 
(B) micro environment which shows various types of interactions 
of the compounds atoms with the amino acid residues. 






): 3375, 3209 (NH), 1686 (C=O), 1600 (C=N), 
1218 (C=S); 
1
H NMR (400 MHz, DMSO-d6) δ: 1.07 
(d, 3H, CH3, J= 4.0 Hz), 3.44-3.49 (m, 2H, CH2-CH3), 
4.17 (s, 2H, benzyl CH2), 5.05 (s, 2H, N-CH2), Ar-H: 
[7.35-7.41 (m, 4H), 7.50 (d, 2H, J= 8.0 Hz ), 7.93 (d, 
2H, J= 8.0 Hz )], 8.08 (s, 1H, NH), 9.32 (s, 1H, NH), 
10.26 (s, 1H, NH); 
13
C(APT) NMR (100 MHz, 
DMSO-d6) δ: 14.92 (CH3), 30.92 (benzyl CH2), 38.93 
(CH2), 50.01 (N-CH2), Ar-C: [127.84 (2CH), 128.87 
(2CH), 129.30 (2CH), 130.07, 131.35 (2CH), 131.91, 
134.14, 135.68], 157.07 (triazole C-3), 159.30 
(triazole C-5), 166.10 (C=O), (C=S, not observed); 
MS (m/z, %): 485.25 ([M+Na]
+
; 3), 381.44 (34), 
360.48 (100), 327.32 (37), 233.21 (21), 120.02 (6).  
2-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]acetyl}-4-benzyl thiosemicarbazide, 
2c: Yield:%93 (4.89 g); mp. 208-209°C; FTIR-ATR 
(ν, cm
-1
): 3341, 3267, 3105 (NH), 1694 (C=O), 1547 
(C=N), 1294 (C=S); 
1
HNMR (400 MHz,DMSO-d6) δ: 
4.14 (s, 2H, benzil-CH2), 4.77 (s, 2H, N-benzyl CH2), 
5.07 (s, 2H, N-CH2), Ar-H: [7.27-7.40 (m, 9H), 7.49 
(d, 2H, J= 8.0 Hz), 7.92 (d, 2H, J= 8.0 Hz)], 8.62  
(s, 1H, NH), 9.53 (s, 1H, NH), 10.36 (s, 1H, NH); 
13
C(APT) NMR (100 MHz,DMSO-d6) δ: 35.69 
(benzyl CH2), 51.90 (N-CH2), 54.77 (N-benzyl CH2), 
Ar-C: [131.88 (CH), 132.04 (2CH), 132.58 (2CH), 
133.31 (2CH), 133.62 (2CH), 134.04 (2CH), 134.81, 
136.10 (2CH), 136.66, 138.89, 140.41, 144.27], 
161.86 (triazole C-3), 164.06 (triazole C-5), 171.01 
(C=O), 174.64 (C=S); MS (m/z, %): 527.42 
([M+2]
+
,5), 381.50 (48), 360.54 (100), 327.32 (38), 
230.33 (8). Anal. Cald. for C25H22Cl2N6OS: C, 57.14; 
H, 4.22; N, 15.99; S, 6.10. Found: C, 57.24; H, 4.21; 
N, 15.68; S, 6.45%. 
2-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]acetyl}-4-phenyl thiosemicarbazide, 
2d: Yield: 92% (4.68 g); mp. 282-283°C; FTIR-ATR 
(ν, cm-1): 3345, 3241, 3154 (NH), 1697 (C=O), 1597 
(C=N), 1279 (C=S); 
1
HNMR (400 MHz,DMSO-d6) δ: 
4.20 (s, 2H, benzyl CH2), 5.12 (s, 2H, N-CH2), Ar-H: 
[7.18-7.41 (m, 9H), 7.50 (d, 2H, J= 8.0 Hz ), 7.93  
(d, 2H, J= 8.0 Hz )], 9.78 (s, 2H, 2NH), 10.53 (s, 1H, 
NH); 
13
C(APT) NMR (100 MHz, DMSO-d6) δ: 30.93 
(benzyl CH2), 50.07 (N-CH2), Ar-C: [125.90 (CH), 
127.85 (2CH), 128.68 (2CH), 128.88 (2CH), 129.30 
(CH), 130.06, 131.28 (2CH), 131.33 (2CH), 131.92, 
134.16, 135.67, 139.37], 157.10 (triazole C-3), 159.36 
(triazole C-5), 166.24 (C=O), 181.50 (C=S); MS  
(m/z, %): 533.17 ([M+Na]+, 24), 511.43 ([M]+,35), 
327.26 (100), 219.20 (51), 114.40 (26). Anal. Cald. 
for C24H20Cl2N6OS: C, 56.36; H, 3.94; N, 16.43; S, 
6.27. Found: C, 56.25; H, 4.00; N, 16.11; S, 6.43%. 
2-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-
1,2,4-triazole-4-yl]acetyl}-4-(4-chlorophenyl) 
thiosemicarbazide, 2e: Yield: 90% (4.67 g); Mp. 
297-298°C; FTIR-ATR (ν, cm
-1
): 3300, 3245, 3169 
(NH), 1690 (C=O), 1593 (C=N), 1277 (C=S); 
1
HNMR (400 MHz, DMSO-d6) δ: 4.20 (s, 2H, benzyl 
CH2), 5.12 (s, 2H, N-CH2), Ar-H: [7.36-7.44 (m, 8H), 
7.50 (d, 2H, J= 8.0 Hz), 7.93 (d, 2H, J= 8.0 Hz)], 9.89 
(s, 2H, 2NH), 10.55 (s, 1H, NH); 
13
C(APT) NMR  
(100 MHz, DMSO-d6) δ:30.94 (benzyl CH2), 50.09 
(N-CH2), Ar-C: [127.85 (2CH), 128.60 (2CH), 128.88 
(2CH), 129.29 (2CH), 130.08 (2C), 131.33 (4CH), 
131.93, 134.16, 135.67, 138.41], 157.08 (triazole  
C-3), 159.36 (triazole C-5), (C=O and C=S,not 





,100), 327.23 (20), 114.10 
(56). Anal. Cald. for C24H19Cl3N6OS: C, 52.81; H, 
3.51; N, 15.40; S, 5.87%; Found: C, 52.74; H, 3.68; 
N, 15.29; S, 5.81%. 
 
General method for the synthesis of compounds, 3a-e 
2N NaOH (100 mL) was added to 10 mL of the 
alcohol solution of compounds 2a-e (0.01 mol),  
and the mixture was refluxed for about 4 hours.  
The progress of the reaction was observed by TLC.  
At the end of this time, rection mixture was cooled  
to room temperature and acidified to pH∼5-6 with 
37% HCl. The resulting white solid was filtered off, 




4-triazole-3-thione, 3a: Yield: 77% (0.51 g); mp. 
219-220°C; FTIR-ATR (ν, cm
-1
): 3091 (NH), 1603, 
1570 (C=N), 1272 (C=S); 
1
H NMR (400 MHz, 
DMSO-d6) δ:3.37 (s, 3H, CH3), 4.30 (s, 2H, benzyl 
CH2), 5.71 (s, 2H, N-CH2), Ar-H: [7.32-7.38 (m, 4H), 
7.50 (d, 2H, J= 8.0 Hz), 7.93 (d, 2H, J= 8.0 Hz)], 
13.76 (s, 1H, SH); 
13
C (APT) NMR (100 MHz, 
DMSO-d6) δ: 30.64 (CH3), 30.66 (benzyl CH2), 43.59 
(N-CH2), Ar-C: [127.93 (2CH), 128.89 (2CH), 129.34 
(2CH), 129.80, 131.16 (2CH), 131.99, 134.35, 
135.36], 148.05 (mercapto-triazol, C-5), 156.72 
(triazole C-3), 159.76 (triazole C-5), 168.09 (triazole 
C-3, C-SH); MS (m/z, %):431.25 ([M]
+
,25), 360.42 
(92), 338.39 (100), 270.13 (27), 114.14 (12). 
5-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]methyl}-4-ethyl-2,4-dihydro-3H-1,2, 




4-triazole-3-thione, 3b: Yield: 69% (0.51 g); mp. 
225-226°C; FTIR-ATR (ν, cm
-1
): 3091 (NH), 1604, 
1586 (C=N), 1274 (C=S);
1
HNMR (400 MHz,DMSO-
d6) δ: 1.06 (t, 3H, J= 8.0 Hz), 4.01 (q, 2H, J= 8.0 Hz), 
4.31 (s, 2H, benzyl CH2), 5.74 (s, 2H, N-CH2), Ar-H: 
[7.31-7.39 (m, 4H), 7.51 (d, 2H, J= 8.0 Hz), 7.93 (d, 
2H, J= 8.0 Hz)], 13.81 (s, 1H, SH); 
13
CNMR (100 
MHz,DMSO-d6) δ: 13.38 (CH3), 30.66 (benzyl CH2), 
39.21 (CH2), 43.59 (N-CH2), Ar-C: [127.93 (2CH), 
128.90 (2CH), 129.37 (2CH), 129.74, 131.16 (2CH), 
132.03, 134.40, 135.25], 147.44 (mercapto-triazole, 
C-5), 156.74 (triazole C-3), 159.78 (triazole C-5), 
167.54 (triazole C-3, C-SH); MS (m/z, %): 447.52 
(68), 445.33 ([M]+, 20), 230.33(100), 200.11 (45). 
Anal. Cald. for C20H18Cl2N6S: C, 53.94; H, 4.07; Cl, 
15.92; N, 18.87; S, 7.20. Found: C, 54.18; H, 3.48; N, 
18.45; S, 7.11%. 
5-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]methyl}-4-benzyl-2,4-dihydro-3H-1,2, 
4-triazole-3-thione, 3c: Yield: 92% (4.68 g); mp. 
172-173°C; FTIR-ATR (ν, cm
-1
): 3091 (NH), 1604, 
1575 (C=N), 1276 (C=S); 
1
H-NMR (400 MHz, 
DMSO-d6) δ: 4.17 (s, 2H, benzyl CH2), 5.35 (s, 2H, 
N-benzyl CH2), 5.55 (s, 2H, N-CH2), Ar-H: [7.15  
(d, 2H, J= 8.0 Hz), 7.19-7.25 (m, 5H), 7.35 (d, 2H,  
J= 8.0 Hz ), 7.47 (d, 2H, J= 8.0 Hz), 7.82 (d, 2H,  
J= 8.0 Hz)], 14.02 (s, 1H, SH); 
13
C-NMR (100 MHz, 
DMSO-d6) δ: 30.66 (benzyl CH2), 43.68 (N-CH2), 
46.50 (N-benzyl CH2), Ar-C: [127.06 (2CH), 127.95 
(2CH), 128.05 (CH), 128.86 (2CH), 128.94 (2CH), 
129.18 (2CH), 129.76, 131.12 (2CH), 131.98, 134.21, 
135.14, 135.39], 147.75 (mercapto-triazole, C-5), 
156.36 (triazole C-3), 159.57 (triazole C-5), 168.77 





, 4), 327.32 (100), 230.33 (20), 
163.20 (18. Anal. Cald. for C25H20Cl2N6S: C, 59.17; 
H, 3.97; N, 16.56; S, 6.32. Found: C, 59.11; H, 3.49; 
N, 16.45; S, 6.44%. 
5-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]methyl}-4-phenyl-2,4-dihydro-3H-1,2, 
4-triazole-3-thione, 3d: Yield: 81% (3.99 g); mp. 
122-123°C; FTIR-ATR (ν, cm
-1
): 3254 (NH), 1596 
(C=N), 1290 (C=S); 
1
HNMR (400 MHz,DMSO-d6) δ: 
3.89 (s, 2H, benzyl CH2), 5.46 (s, 2H, N-CH2), Ar-H: 
[ 7.19 (d, 2H, J= 8.0 Hz ), 7.29-7.37 (m, 4H), 7.47-
7.49 (m, 5H), 7.83 (d, 2H, J= 8.0 Hz)], 14.05 (s, 1H, 
SH); 
13
CNMR (100 MHz,DMSO-d6) δ: 30.37 (benzyl 
CH2), 43.83 (N-CH2), Ar-C: [127.91 (2CH), 128.31 
(2CH), 128.89 (2CH), 129.27 (2CH), 129.73,129.85 
(2CH) 130.21 (CH), 131.08 (2CH), 131.98,133.33 
134.28, 135.05], 147.41 (mercapto-triazole, C-5), 
156.33 (triazole C-3), 159.58 (triazole C-5), 169.15 
(triazole C-3, C-SH); MS (m/z, %):493.32 ([M]
+
, 5), 
381.50 (60), 360.54 (100), 327.32 (40), 230.33 (30). 
5-{[3-(4-Chlorobenzyl)-5-(4-chlorophenyl)-1H-1,2, 
4-triazole-4-yl]methyl}-4-(p-chlorophenyl-2,4-
dihydro-3H-1,2,4-triazole-3-thione, 3e: Yield: 82% 
(4.32 g); mp. 195-196°C; FTIR-ATR (ν, cm
-1
): 1571 
(C=N), 1226 (C=S); 
1
HNMR (400 MHz, DMSO-d6) 
δ: 4.02 (s, 2H, benzyl CH2), 5.50 (s, 2H, N-CH2), Ar-
H: [7.20 (d, 2H, J= 8.0 Hz ), 7.34-7.37 (m, 4H), 7.47-
7.55 (m, 4H), 7.82 (d, 2H, J= 8.0 Hz)], 14.06 (s, 1H, 
SH);
 13
CNMR (100 MHz,DMSO-d6) δ: 30.51 (benzyl 
CH2), 43.89 (N-CH2), Ar-C: [ 127.91 (2CH), 128.88 
(2CH), 129.26 (2CH), 129.68, 129.89 (2CH), 130.31 
(CH), 131.04 (2CH), 131.23 (CH), 132.06, 132.21, 
134.31, 134.93, 135.59], 147.30 (mercapto-triazole, 
C-5), 156.31 (triazole C-3), 159.51 (triazole C-5), 
169.16 (triazole C-3, C-SH);MS (m/z,%): 529.23 (10), 
527.36 ([M+1]+, 19), 381.44 (54), 360.48 (100), 
188.85 (82). Anal. Cald. for C24H17Cl3N6S: C, 54.61; 
H, 3.25; N, 15.92; S, 6.07. Found: C, 54.99; H, 3.00; 
N, 16.26; S, 5.92%. 
 
General method for the synthesis of compounds,4a-e 
The compounds 3a-e (0.01 mol) and 1-
phenylpiperazine (0.01 mol, 1.54 mL) were dissolved 
in DMF (10 mL). Later on, formaldehyde (37%,  
1.12 mL, 0.015 mol) was added dropwise this solution 
and this mixture was stirred for about 16 h at room 
temperature. Reaction times were followed up by 
TLC. At the end of this period, the mixing was 
emptied into cold water. The resulting white 
precipitate solid was filtered off, washed with cold 
water and recrystallized from benzene:petroleum 




triazole-3-thione, 4a: Yield: 99% (5.99 g); mp. 182-
183°C; FTIR-ATR (ν, cm
-1
): 1598, 1577 (C=N), 1232 
(C=S), 1164 (N-CH2-N); 
1
HNMR (400 MHz, DMSO-
d6) δ: 2.74 (bs, 4H, N-phenylpiperazin, 2CH2), 3.07 
(bs, 4H, N-phenylpiperazin, 2CH2), 3.31 (s, 3H, CH3), 
4.32 (s, 2H, benzyl CH2), 5.01 (s, 2H, N-CH2-N), 5.76 
(s, 2H, N-CH2), Ar-H: [6.76 (t, 1H, J= 8.0 Hz), 6.87 (d, 
2H, J= 8.0 Hz), 7.18 (t, 2H, J= 8.0 Hz ), 7.31-7.37 (m, 
5H), 7.43-7.45 (m, 3H)]; 13CNMR (100 MHz, DMSO-
d6) δ: 30.73 (benzyl CH2), 31.79 (CH3), 43.44 (N-CH2), 
48.68 (N-phenylpiperazin, C-2 and C-6), 50.17 (N-




phenylpiperazin, C-3 and C-5), 68.91 (N-CH2-N), Ar-
C: [116.02 (2CH), 119.37 (CH), 127.92 (2CH), 128.90 
(2CH), 129.34 (4CH), 129.80, 131.12 (2CH), 131.96, 
134.34, 135.31, 151.42], 146.83 (mercapto-triazole, C-
5), 156.72 (triazole C-3), 159.74 (triazole C-5), 169.08 
(C=S); MS (m/z, %):605.23 ([M+1]
+
, 22), 511.66 (5), 
500.59 (100), 487.06 (11). Anal. Cald. for 
C30H30Cl2N8S: C, 59.50; H, 4.99; N, 18.50; S, 5.29. 




triazole-3-thione, 4b: Yield: 67% (4.24 g); mp. 206-
207°C; FTIR-ATR (ν, cm
-1
): 1598, 1577 (C=N), 1232 
(C=S), 1161 (N-CH2-N); 
1
HNMR (400 MHz, DMSO-
d6) δ: 1.06 (t, 3H, CH3, J= 8,0 Hz), 2.75 (bs, 4H,  
N-phenylpiperazin, 2CH2), 3.07 (bs, 4H,  
N-phenylpiperazin, 2CH2), 4.05 (q, 2H, J= 8,0 Hz), 
4.34 (s, 2H, benzyl CH2), 5.03 (s, 2H, N-CH2-N), 5.80 
(s, 2H, N-CH2), Ar-H: [6.77 (t, 1H, J= 8,0 Hz), 6.87 
(d, 2H, J= 8.0 Hz), 7.19 (t, 2H, J= 8,0 Hz), 7.31-7.38 
(m, 4H), 7.41-7.53 (m, 2H), 7.92 (d, 2H, J= 8.0 Hz)];
 
13CNMR (100 MHz,DMSO-d6,) δ: 13.13 (CH3),  
30.76 (benzyl CH2), 40.27 (CH2), 43.35 (N-CH2), 
48.68 (N-phenylpiperazin, C-2 and C-6), 50.23  
(N-phenylpiperazin, C-3 and C-5), 68.73 (N-CH2-N), 
Ar-C: [116.02 (2CH), 119.40 (CH), 127.89 (2CH), 
128.78 (2CH), 128.91 (2CH), 129.34 (2CH), 129.73, 
131.14 (2CH), 132.00, 134.39, 135.21, 151.45], 
146.18 (mercapto-triazole, C-5), 156.72 (triazole  
C-3), 159.77 (triazole C-5), 168.45 (C=S); MS (m/z, 
%): 659.26 ([M+Na]
+
, 10), 641.24 (35), 619.27 (100). 
Anal. Cald. for C31H32Cl2N8S: C, 60.09; H, 5.21; N, 





triazole-3-thione, 4c: Yield: 96% (6.74 g); mp. 176-
177°C; FTIR-ATR (ν, cm
-1
): 1599, 1577 (C=N), 1233 
(C=S), 1160 (N-CH2-N); 
1
HNMR (400 MHz,DMSO-
d6,) δ: 2.80 (bs, 4H, N-phenylpiperazin, 2CH2), 3.10 
(bs, 4H, N-phenylpiperazin, 2CH2), 4.18 (s, 2H, 
benzyl CH2), 5.13 (s, 2H, N-CH2-N), 5.40 (s, 2H, N-
benzyl CH2), 5.62 (s, 2H, N-CH2), Ar-H: [ 6.78 (t, 1H, 
J= 8.0 Hz ), 6.89 (d, 2H, J= 8.0 Hz), 6.99-7.25 (m, 
9H), 7.33-7.42 (m, 4H), 7.79 (d, 2H, J= 8.0 Hz)];
 
13CNMR (100 MHz,DMSO-d6) δ: 30.72 (benzyl 
CH2), 43.47 (N-CH2), 47.56 (N-benzyl CH2), 48.70 
(N-phenylpiperazin, C-2 and C-6), 50.24 (N-
phenylpiperazin, C-3 and C-5), 69.21 (N-CH2-N), Ar-
C: [ 116.02 (2CH), 119.42 (2CH), 126.84 (2CH), 
127.89 (2CH), 128.03 (2CH), 128.91 (2CH), 129.15 
(2CH), 129.35 (2CH), 129.75, 131.12 (2CH), 131.96 
(2C), 134.18, 135.12, 151.44], 146.99 (mercapto-
triazole, C-5), 156.30 (triazole C-3), 159.55 (triazole 





, 31), 611.43 (35), 538.54 (35), 
537.54 (100). Anal. Cald. for C36H34Cl2N8S: C, 63.43; 
H, 5.03; N, 16.44; S, 4.70. Found: C, 63.94; H, 5.15; 




triazole-3-thione, 4d: Yield: 98% (6.53 g); mp. 163-
164°C; FTIR-ATR (ν, cm
-1
): 1599, 1578 (C=N), 1238 
(C=S) 1156 (N-CH2-N); 
1
HNMR (400 MHz, DMSO-
d6) δ: 2.88 (bs, 4H, N-phenylpiperazin, 2CH2), 3.13 
(bs, 4H, N-phenylpiperazin, 2CH2), 3.91 (s, 2H, 
benzyl CH2), 5.16 (s, 2H, N-CH2-N), 5.52 (s, 2H,  
N-CH2), Ar-H: [6.79 (t, 1H, J= 8.0 Hz ), 6.92 (d, 2H, 
J= 8.0 Hz), 7.18-7.23 (m, 4H), 7.30-7.39 (m, 6H). 
7.49-7.50 (m, 3H), 7.82 (d, 2H, J= 8,0 Hz)]; 13CNMR 
(100 MHz,DMSO-d6) δ: 30.42 (benzyl CH2), 43.73 
(N-CH2), 48.75 (N-phenylpiperazin, C-2 and C-6), 
50.33 (N-phenylpiperazin, C-3 and C-5), 69.11  
(N-CH2-N), Ar-C: [116.04 (2CH), 119.45 (CH), 
127.86 (2CH), 128.30 (CH), 128.90 (2CH), 129.24 
(2CH), 129.37 (2CH), 129.72, 129.91 (2CH), 130.35 
(2CH), 131.04 (2CH), 131.97, 133.77, 134.27, 
135.01, 151.51], 146.05 (mercapto-triazole, C-5), 
156.27 (triazole C-3), 159.57 (triazole C-5), 170.05 





, 20), 655.12 (52), 
564.66 (15). Anal. Cald. for C35H32Cl2N8S: C, 62.96; 
H, 4.83; N, 16.78; S, 4.80. Found: C, 62.84; H, 4.99; 




triazole-3-thione, 4e: Yield: 91% (6.40 g); mp. 177-
178°C; FTIR-ATR (ν, cm
-1
): 1599, 1579 (C=N), 1233 
(C=S) 1168 (N-CH2-N); 
1
H NMR (400 MHz, DMSO-
d6) δ: 2.86 (bs, 4H, N-phenylpiperazin, 2CH2), 3.12 
(bs, 4H, N-phenylpiperazin, 2CH2), 4,03 (s, 2H, 
benzyl CH2), 5.13 (s, 2H, N-CH2-N), 5.55 (s, 2H,  
N-CH2), Ar-H: [6.78 (t, 1H, J= 8.0 Hz), 6.91 (d, 2H, 
J= 12.0 Hz), 7.18-7.22 (m, 4H), 7.35-7.40 (m, 6H), 
7.54 (d, 2H, J= 8.0 Hz), 7.81 (d, 2H, J= 12.0 Hz)];
 
13
CNMR (100 MHz, DMSO-d6,) δ: 30.55 (benzyl 




CH2), 43.78 (N-CH2), 48.75 (N-phenylpiperazin, C-2 
and C-6), 50.28 (N-phenylpiperazin, C-3 and C-5), 
69.18 (N-CH2-N), Ar-C: [116.05 (2CH), 119.46 (CH), 
127.86 (2CH), 128.90 (2CH), 129.24 (2CH), 129.37 
(2CH), 129.64, 129.95 (2CH), 130.29 (2CH), 130.99 
(2CH), 132.02, 132.63, 134.29, 134.89 135.13, 
151.49], 145.92 (mercapto-triazole, C-5), 156.25 
(triazole C-3), 159.47 (triazol C-5), 169.99 (C=S); MS 
(m/z, %): 739.49 ([M+K]+, 10), 723.23 ([M+Na]+, 
15), 527.18 (61), 500.50 (100), 497.18 (22). Anal. 
Cald. for C35H31Cl3N8S: C, C, 59.87; H, 4.45; N, 
15.96; S, 4.57. Found: C, 59.37; H, 4.30; N, 15.75; S, 
4.66%. 
 
Pancreatic porcine lipase (PPL) activity assay, 
optimization and inhibition 
PPL activity was determined by a method adapted 
from earlier studies in the literature
34,35
. The reaction 
mixture contained 20 µL of p-NPB (8.4 mM; 
dissolved in DMSO), 60 µL of PPL (8 mg/mL; 10 mM 
in pH 7.0 MOPS buffer containing 1 mM EDTA) and 
100 mM pH 8.0 Tris-HCl buffer containing 5 mM 
CaCl2 to make final volume to 1.2 mL. The reaction 
mixture was incubated at 37°C for 15 min and then 
the reaction was stopped by adding 500 µL acetone. 
The absorbance of p-nitrophenol released was 
measured at A405. One unit of enzyme activity was 
described as the amount of µmol p-nitrophenol 
released in per minute under standard reaction 
conditions36. The enzyme optimization studies were 
carried out before starting the inhibition studies for 
avoiding mistakes. The studies included optimum pH 
and temperature, optimum protein concentration and 
Km values
37
. For inhibition studies, stock solution of 
organic molecules and orlistat as a positive control 
against PPL, were prepared in DMSO. 20 µL of each 
inhibitor solutions were mixed with 60 µL of PPL 
solution and preincubated at 37°C for 15 min. The 
control mixture was prepared using organic 
solvent rather than an inhibitor solution. All 
samples were assayed in triplicate. For each organic 
molecule, percentage relative activity was plotted 
against inhibitor concentration. The IC50 value was 
defined as the concentrations of inhibitors required to 
reach 50% inhibition of lipase activity. 
 
Computational analysis 
Before performing docking studies, Spartan 16 
software was used for optimising the new fifteen 
inhibitor organic molecules38. Crystalline structure of 
the porcin pancreatic lipase (1ETH) as target enzyme 
was found from literature
39
 and then obtained from 
the Protein Data Bank (www.rcsb.org) in the PDB 
format. Autodock Tools-1.5.6 for in silico purification 
of the target enzyme’s crystall structure, AutoDock 
Vina 1.1.2
40
 for the investigation of the ligand-protein 
interactions in the binding pocket and calculation of 
binding energies of the organic molecules and, 
Discovery Studio 4.5 Client for highlighting 
interactions between receptor and ligands were used 
as softwares, respectively. 
 
Conclusion 
In this study, fifteen new molecules bearing 1,2,4-
triazole core were synthesized and evaluated for their 
antilipase activity due to the medical importance of 
lipase inhibition. Molecule 2e among the tested 
substances was found the most potential for lipase 
inhibition with its IC50 value in the micromolar level. 
It may be recommended that pharmacological 
researches related to lipase inhibition of 2e molecule 
should be focused on. 
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